Basilea Pharmaceutica (OTCMKTS:BPMUF) Upgraded at Zacks Research

Zacks Research upgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) to a hold rating in a report issued on Wednesday,Zacks.com reports.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS BPMUF opened at $67.75 on Wednesday. The stock’s 50-day moving average is $66.85 and its two-hundred day moving average is $57.91. The company has a debt-to-equity ratio of 1.18, a quick ratio of 4.16 and a current ratio of 4.85. Basilea Pharmaceutica has a 1-year low of $47.50 and a 1-year high of $67.75.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.